Get the Stockscreener App
96.29
0.83%
0.771
Revolution Medicines Inc stock is traded at $96.29, with a volume of 456.16K.
It is up +0.83% in the last 24 hours and down -6.71% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
See More
Previous Close:
$95.52
Open:
$96.54
24h Volume:
456.16K
Relative Volume:
0.14
Market Cap:
$19.09B
Revenue:
$742.00K
Net Income/Loss:
$-1.13B
P/E Ratio:
-16.27
EPS:
-5.9165
Net Cash Flow:
$-913.73M
1W Performance:
-1.83%
1M Performance:
-6.71%
6M Performance:
+126.56%
1Y Performance:
+150.48%
1-Day Range:
$94.29
$96.54
1-Week Range:
$94.29
$100.08
52-Week Range:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
96.31 | 18.93B | 742.00K | -1.13B | -913.73M | -5.9165 |
VRTX
Vertex Pharmaceuticals Inc
|
454.56 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.45 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
693.27 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.68 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.16 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Feb-27-26 | Resumed | UBS | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Wedbush Reiterates Revolution Medicines (RVMD) Outperform Recommendation - MSN
(RVMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating - MSN
A Look At Revolution Medicines (RVMD) Valuation After AACR RAS(ON) Pipeline Data Catalyst - simplywall.st
Revolution Medicines COO Horn sells $455,918 in shares By Investing.com - Investing.com South Africa
Revolution Medicines Eyes Guidance with Mixed Signals from Financial Reports - timothysykes.com
Revolution Medicines rises on daraxonrasib data that supports phase 3 program - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Revolution Medicines Insider Sold Shares Worth $455,919, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines Insider Sold Shares Worth $1,280,412, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines Insider Sold Shares Worth $427,965, According to a Recent SEC Filing - marketscreener.com
Wang Xiaolin, evp at Revolution Medicines, sells $199k in RVMD - Investing.com
Anders, Revolution Medicines CFO, sells $273k in RVMD stock - Investing.com
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,010 Shares of Stock - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,073 Shares - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 12,871 Shares - MarketBeat
Cislini, Revolution Medicines general counsel, sells $291,889 in RVMD stock By Investing.com - Investing.com India
Cislini, Revolution Medicines general counsel, sells $291,889 in RVMD stock - Investing.com
Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 2,753 Shares of Stock - MarketBeat
Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells 4,583 Shares of Stock - MarketBeat
Wang Xiaolin, evp at Revolution Medicines, sells $199k in RVMD By Investing.com - Investing.com India
Revolution Medicines exec Kelsey sells $427,964 in stock By Investing.com - Investing.com India
Anders, Revolution Medicines CFO, sells $273k in RVMD stock By Investing.com - Investing.com India
Revolution Medicines CEO Goldsmith sells $1.28 million in stock - Investing.com
Revolution Medicines exec Kelsey sells $427,964 in stock - Investing.com
Revolution Medicines COO Horn sells $455,918 in shares - Investing.com
Revolution Medicines CEO Goldsmith sells $1.28 million in stock By Investing.com - Investing.com Australia
Wei Lin, chief medical officer, sells $206k in Revolution Medicines - Investing.com
Revolution Medicines (NASDAQ: RVMD) CMO sells 2,073 shares for tax withholding - Stock Titan
Revolution Medicines (RVMD) officer sells 4,302 shares under 10b5-1 plan - Stock Titan
Revolution Medicines (RVMD) director sells 12,871 shares in 10b5-1 trade - Stock Titan
Revolution Medicines (RVMD) COO pre-planned sale tied to RSU tax - Stock Titan
CFO of Revolution Medicines (NASDAQ: RVMD) sells 2,753 shares - Stock Titan
Revolution Medicines (RVMD) counsel sells 2,958 pre-planned shares - Stock Titan
Revolution Medicines (RVMD) insider sale under 10b5-1 plan for RSU taxes - Stock Titan
Morgan Stanley schedules sale of RVMD (NASDAQ: RVMD) RSUs, prior insider sales listed - Stock Titan
Revolution Medicines (RVMD) Among Top Biotech M&A Targets - GuruFocus
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech - Seeking Alpha
Revolution Medicines, Inc. (RVMD) net loss widens amid progress on clinical trial programs - MSN
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
Stifel Reiterates Revolution Medicines (RVMD) Buy Recommendation - MSN
Wells Fargo Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
Revolution Medicines Secures $2 Billion Flexible Financing Deal with Royalty Pharma - MSN
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Bitget
Revolution Medicines Showcases RAS(ON) Inhibitor Pipeline Advances at AACR Annual Meeting 2026 - Quiver Quantitative
Revolution Medicines to Showcase Progress Across RAS(ON) - GlobeNewswire
Revolution Medicines brings lung and pancreatic cancer trial data to AACR 2026 - Stock Titan
Algert Global LLC Boosts Position in Revolution Medicines, Inc. $RVMD - MarketBeat
RVMD: Jefferies Raises Price Target for Revolution Medicines to $140 | RVMD Stock News - GuruFocus
RVMD SEC FilingsRevolution Medicines, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):